


The Most Powerful Antioxidant: Melatonin
最強抗氧化物質: 褪黑激素
褪黑激素,不僅僅是調節睡眠的激素,更是一種強效的抗氧化劑。最新的研究表明,褪黑激素具有顯著的抗氧化和抗炎作用,這些特性在維持身體的功能和穩定狀態中發揮著重要作用。
根據最新的文獻中提到,褪黑激素通過直接和間接的機制發揮抗氧化作用,這使得它成為對抗有毒的氧和氮自由基的內源性保護劑。文中提到:「褪黑激素及其代謝產物創造了一個抗氧化級聯反應,通過多種機制限制了氧化損傷」。* 1
此外,褪黑激素還能誘導內源性抗氧化酶,如超氧化物歧化酶、過氧化氫酶和穀胱甘肽過氧化酶,從而加強其抗氧化效果。這些特性使褪黑激素成為一種多功能的分子,能夠有效地抵禦氧化應激並維持身體的健康。
相較於其他常見的抗氧化劑,如維生素C和維生素E,褪黑激素具有多方面的優勢和特點。首先,褪黑激素能夠穿透所有的細胞膜和血腦屏障,這使得它能夠在全身各個部位發揮作用 * 2。其次,褪黑激素的抗氧化效果不僅僅依賴於自身,還包括其代謝產物的抗氧化作用,形成了一個「抗氧化級聯反應」* 3。這意味著褪黑激素在中和自由基後,其代謝產物仍然具有抗氧化能力,進一步延長和增強其保護作用。
透過這些研究,我們可以更好地理解褪黑激素在抗氧化和抗炎症中的作用,並探索其在臨床治療中的潛力 * 4
Reference: 1. Chitimus DM, Popescu MR, Voiculescu SE, Panaitescu AM, Pavel B, Zagrean L, Zagrean A-M. Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease. Biomolecules. 2020; 10(9):1211. https://doi.org/10.3390/biom10091211. 2.Chitimus DM, Popescu MR, Voiculescu SE, Panaitescu AM, Pavel B, Zagrean L, Zagrean A-M. Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease. Biomolecules. 2020; 10(9):1211. https://doi.org/10.3390/biom10091211. AMA Style
Bantounou M, Plascevic J, Galley HF. Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions. Antioxidants. 2022; 11(3):532. https://doi.org/10.3390/antiox11030532 4. Bantounou M, Plascevic J, Galley HF. Melatonin and Related Compounds: Antioxidant and Anti-Inflammatory Actions. Antioxidants. 2022; 11(3):532. https://doi.org/10.3390/antiox11030532 .



Reference: Mendes L, Queiroz M, Sena CM. Melatonin and Vascular Function. Antioxidants. 2024; 13(6):747. https://doi.org/10.3390/antiox13060747

褪黑激素運用之臨床範疇
THE CLINICAL APPLICATION OF DISEASE MANAGEMENT IN LITERATURE


褪黑激素運用於女性
.png)


褪黑激素運用於年長者
.png)

.png)
褪黑激素運用於兒童
1. Castelli, V., Iannotta, D., Lombardi, F., et al. (2023). Melatonin in ocular health and disease: Mechanisms and therapeutic potential. International Journal of Molecular Sciences, 24(6), 5829.
2. Zhang, H., Zhang, Y., & Zhang, D. D. (2024). The role of melatonin in eye diseases: A review of current research and future perspectives. Experimental Eye Research, 230, 109547.
3. Ravindra, P. N., Jain, S., & Dhanasekaran, M. (2024). Role of melatonin in insomnia and other sleep disorders: A review of mechanisms and therapeutic potential. Sleep Medicine Reviews, 75, 101796.
4. Hosseinzadeh A, Kamrava SK, Moore BCJ, Reiter RJ, Ghaznavi H, Kamali M, Mehrzadi S. Molecular Aspects of Melatonin Treatment in Tinnitus: A Review. Curr Drug Targets. 2019;20(11):1112-1128. doi: 10.2174/1389450120666190319162147. PMID: 30892162.
5. Xu L, Li H, Zhang O, Zhang F,Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis. J Mol Endocrinol. 2022 Dec 12;70(1):e220075. doi: 10.1530/JME-22-0075. PMID: 36356262.
6. Luo Z, Tang YY, Zhou L. Melatonin as an adjunctive therapy in cardiovascular disease management. Sci Prog. 2024 Oct-Dec;107(4):368504241299993. doi: 10.1177/00368504241299993. PMID: 39574322; PMCID: PMC11585022.
7. Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z, Zisapel N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006 Oct;119(10):898-902. doi: 10.1016/j.amjmed.2006.02.002. PMID: 17000226.
8. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes. Epub 2011 Aug 2. PMID: 21887103; PMCID: PMC3160855.
9. Brzozowska I, Strzalka M. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des. 2014;20(30):4807-15.
10. Faghih Dinevari M. The effect of melatonin on irritable bowel syndrome patients with and without sleep disorders: a randomized double-blinded placebo-controlled trial study. BMC Gastroenterol. 2023 Apr 25;23(1):135. doi: 10.1186/s12876-023-02760-0. PMID: 37098505; PMCID: PMC10131443.
11. Burke CA, Nitti VW, Stothers L. Melatonin and melatonin receptor agonists in the treatment of nocturia: A systematic review. Neurourol Urodyn. 2024 Apr;43(4):826-839. doi: 10.1002/nau.25443. Epub 2024 Mar 8. PMID: 38456646.
13. Demirhan Kayacik A. Effects of melatonin intake on depression and anxiety in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2024 Apr;27(2):265-273. Epub 2023 Nov 9. PMID: 37945913.
14. Nexha A, Caropreso L,. Biological rhythms in premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. BMC Womens Health. 2024 Oct 7;24(1):551. doi: 10.1186/s12905-024-03395-3. PMID: 39375682; PMCID: PMC11457342.
15. Su CM, Tsai CH, Chen HT, Wu YS, Yang SF, Tang CH. Melatonin Regulates Rheumatoid Synovial Fibroblasts-Related Inflammation: Implications for Pathological Skeletal Muscle Treatment. J Pineal Res. 2024 Sep;76(6):e13009. doi: 10.1111/jpi.13009. PMID: 39315577.
16. Chen Y, Yang C, Deng Z, Xiang T, Ni Q, Xu J, Sun D, Luo F. Gut microbially produced tryptophan metabolite melatonin ameliorates osteoporosis via modulating SCFA and TMAO metabolism. J Pineal Res. 2024 Apr;76(3):e12954. doi: 10.1111/jpi.12954. PMID: 38618998.
17. Toffol E, Kalleinen N. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014 May;21(5):493-500. doi: 10.1097/GME.0b013e3182a6c8f3. PMID: 24065140.
18. Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014 May;56(4):371-81. doi: 10.1111/jpi.12137. Epub 2014 Apr 5. PMID: 24654916.
20. Hosseinzadeh A, Alinaghian N, Sheibani M, Seirafianpour F, Naeini AJ, Mehrzadi S. Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases. Life Sci. 2024 May 1;344:122557. doi: 10.1016/j.lfs.2024.122557. Epub 2024 Mar 11. PMID: 38479596.
21. Ziaei S, Hasani M. Effect of melatonin supplementation on cardiometabolic risk factors, oxidative stress and hormonal profile in PCOS patients: a systematic review and meta-analysis of randomized clinical trials. J Ovarian Res. 2024 Jul 4;17(1):138.
22. Zhang X, Man X. Melatonin protects against particulate matter-induced ovarian dysfunction by activating the Nrf2 signaling pathway to alleviate ferroptosis. Life Sci. 2024 Dec 15;359:123200. doi: 10.1016/j.lfs.2024.123200. Epub 2024 Nov 4. PMID: 39505297.
23. Tsui KH, Li CJ, Lin LT. Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age. Reprod Biol Endocrinol. 2024 Nov 8;22(1):138.
24. Liu, J., et al. (2024). The role of melatonin in neurodegenerative diseases: Insights into Alzheimer's and Parkinson's disease. Frontiers in Aging Neuroscience, 16, 1334567.
25. Posa, L., De Gregorio, D., Gobbi, G., & Comai, S. (2018). Targeting melatonin MT2 receptors: a novel pharmacological avenue for inflammatory and neuropathic pain. Current Medicinal Chemistry, 25(32), 3866-3882.
26. Liu, Y., Zhang, Z., Li, J., Wang, Y., & Chen, Y. (2024). Sleep disturbance in children with attention-deficit hyperactivity disorder: relationship with melatonin and behavior
27. Xu, Z., Wang, L., Chen, Y., Li, J., & Zhang, X. (2024). Melatonin as a potential therapeutic agent for atopic dermatitis: Mechanisms and clinical evidence. International Journal of Molecular Sciences, 25(4), 5678.
28. Ma, Z., Li, Q., Wang, Y., & Chen, X. (2023). Melatonin and its potential role in inflammatory skin diseases. International Journal of Molecular Sciences, 24(2), 1567.
29. Chang, Y. S., Lin, M. H., Lee, J. H., Lee, P. L., Dai, Y. S., Chu, K. H., & Chen, Y. J. (2016). Melatonin supplementation for children with atopic dermatitis and sleep disturbance: A randomized clinical trial. JAMA Pediatrics, 170(1), 35-42.
30. Wang, Y., Li, X., Zhang, Z., Chen, J., & Liu, Y. (2023). Melatonin in dermatological diseases: Mechanisms and therapeutic potential. Biomedicine & Pharmacotherapy, 165, 115230.
31. Mombelli S, Bacaro V, Curati S, Berra F, Sforza M, Castronovo V, Ferini-Strambi L, Galbiati A, Baglioni C. Non-pharmacological and melatonin interventions for pediatric sleep initiation and maintenance problems: A systematic review and network meta-analysis. Sleep Med Rev. 2023 Aug;70:101806. doi: 10.1016/j.smrv.2023.101806. Epub 2023 Jun 16. PMID: 37406497.
32. Overberg J, Kalveram L, Keller T, Krude H, Kühnen P, Wiegand S. Interactions between nocturnal melatonin secretion, metabolism, and sleeping behavior in adolescents with obesity. Int J Obes (Lond). 2022 May;46(5):1051-1058. doi: 10.1038/s41366-022-01077-4. Epub 2022 Feb 9.
33. Gombert M, Martin-Carbonell V, Pin-Arboledas G, Carrasco-Luna J, Carrasco-García Á, Codoñer-Franch P. Melatonin Levels in Children with Obesity Are Associated with Metabolic Risk and Inflammatory Parameters. Nutrients. 2021 Oct 16;13(10):3629.

.png)
.png)
不是所有褪黑激素都是一樣的。
在選擇褪黑激素產品時,首先必須要先了解主要成分之生產方式。在台灣,藥事法規範只能購買含有藥品許可證之褪黑激素,其分子為經 GMP/ PICS 認證之藥廠製造合成、批次品質及劑量穩定 ; 而國外 (如: 美國等, ...) 在一般超市即可買到的褪黑激素為食品,萃取來源多為牛、豬隻或少數萃取源為植物。






.png)
.png)
再者,選擇適合自己的褪黑激素錠劑釋放方式: 短效型或長效釋放型。短效立即釋放型會在3小時左右將活性成分全部釋放; 而長效釋放型則模仿人體自然分泌節奏,逐步並延長釋放8小時,幫助維持更長時間的睡眠。選擇適合自己的褪黑激素類型,可依個人的睡眠需求和生活方式做決定。








我覺得褪黑激素跟
安眠藥不一樣! 以前都
不知道怎麼睡著的!
現在我能感覺到
"睡意" 了!

本來以為能順利睡著就很好了!
沒想到 連續服用 第3個月 的時候
我擁有從來沒有過的睡眠品質!

醫師跟我說
藥品級的褪黑
激素純度很高!
每天一粒2毫克
就足夠囉!




" Your Health
Our priority "
法諾亞生技藥品股份有限公司成立於2013年,我們致力於研發及製造獨特及高品質的醫療藥品,為醫藥領域、醫護人員及病患提供更好的藥物治療選擇。
Biofrontier was founded in 2013 and is now a fast-growing specialty generics company in Asia. Biofrontier focuses on developing and promoting innovative and generic pharmaceutical products. We help meet unmet needs.




本網站內容僅供您了解相關資訊,如有相關問題請加入官方line,獲得進一步資訊。
藥商: 法諾亞生技藥品股份有限公司